SCHEMBL6975269

SCHEMBL6975269

COc1cc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)ccc1N1CCN(C)CC1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 15/20 0.86
HTR1A P08908 9/20 0.86
HTR1D P28221 9/20 0.86
HTR1B P28222 9/20 0.86
HTR7 P34969 6/20 0.86
DRD2 P14416 6/20 0.86
ADRA1B P35368 6/20 0.86
DRD3 P35462 6/20 0.86
HTR2A P28223 6/20 0.86
HTR2C P28335 6/20 0.86
HTR4 Q13639 5/20 0.86
HTR2B P41595 5/20 0.86
HTR1E P28566 3/20 0.86
HTR1F P30939 3/20 0.86
DRD1 P21728 1/20 0.71
DRD4 P21917 1/20 0.71
CYP1A2 P05177 1/20 0.70
ADRB1 P08588 1/20 0.70
CYP3A4 P08684 1/20 0.70
ADRA2A P08913 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1136525 0.93 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL29496144 0.93 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6981823 0.87 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6972216 0.87 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6980956 0.85 HTR6 (0.77) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6979823 0.85 HTR6 (0.82) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6981982 0.85 HTR6 (0.82) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL29386932 0.83 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL194700 0.83 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL7195128 0.82 HTR6 (0.72) HTR6HTR1AHTR1DHTR1BHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP claimed
EP-0946539-B1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 2003-08-13 EP disclosed
US-6599904-B2 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-29 US disclosed
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments SMITHKLINE BEECHAM P.L.C. 2003-04-10 US disclosed
US-6423717-B1 NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-23 US disclosed
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP disclosed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069233-A1 Sulphonamide derivatives, process for their preparation, and their use as medicaments TPMT, MPST, STS HTR6 1537/4885HTR1A 2960/4885HTR1D 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.